Caribou Biosciences Raises $115M Series C Financing to Advance Next-Generation CRISPR Technologies and Allogeneic Cell Therapy Pipeline

05 Mar, 2021

Caribou Biosciences Raises $115M Series C Financing to Advance Next-Generation CRISPR Technologies and Allogeneic Cell Therapy Pipeline
Photo by Mike Kononov on Unsplash

– Caribou Biosciences, Inc. announced the successful completion of an oversubscribed $115m Series C financing.
– Proceeds from the financing will be used to further develop the Company’s proprietary, next-generation CRISPR technology platform and to advance the Company’s pipeline of wholly-owned allogeneic immune cell therapies for oncology with best-in-class potential.
– The Series C financing was co-led by new premier healthcare investors Farallon Capital Management, PFM Health Sciences, and Ridgeback Capital Investments.

Biotechnology Health Care North America Therapeutics
Crunchbase icon

Content report

The following text will be sent to our editors: